(Q28186580)

English

Safeguarding patients in clinical trials with high mortality rates

scientific article (publication date: 15 July 2001)

In more languages

edit

Statements

instance of

scholarly article

0 references

title

Safeguarding patients in clinical trials with high mortality rates (English)

0 references

author name string

B D Freeman

series ordinal

1

0 references

R L Danner

series ordinal

2

0 references

S M Banks

series ordinal

3

0 references

C Natanson

series ordinal

4

0 references

language of work or name

English

0 references

publication date

15 July 2001

0 references

published in

American Journal of Respiratory and Critical Care Medicine

0 references

volume

164

0 references

issue

2

0 references

page(s)

190-2

0 references

cites work

Increased mortality associated with growth hormone treatment in critically ill adults

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1164%2FAJRCCM.164.2.2011028

retrieved

21 January 2018

Critical-care studies: redefining the rules.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1164%2FAJRCCM.164.2.2011028

retrieved

21 January 2018

Phase I study of the safety and pharmacologic effects of diaspirin cross-linked hemoglobin solution

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1164%2FAJRCCM.164.2.2011028

retrieved

21 January 2018

Initial evaluation of diaspirin cross-linked hemoglobin (DCLHb) as a vasopressor in critically ill patients

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1164%2FAJRCCM.164.2.2011028

retrieved

21 January 2018

Protective and pathological roles of nitric oxide in endotoxin shock

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1164%2FAJRCCM.164.2.2011028

retrieved

21 January 2018

Time-dependent enhancement or inhibition of endotoxin-induced vascular injury in rat intestine by nitric oxide synthase inhibitors

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1164%2FAJRCCM.164.2.2011028

retrieved

21 January 2018

Inhibition of nitric oxide synthesis in septic shock: how much is beneficial?

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1164%2FAJRCCM.164.2.2011028

retrieved

21 January 2018

An open-label dose escalation study of the nitric oxide synthase inhibitor, N(G)-methyl-L-arginine hydrochloride (546C88), in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1164%2FAJRCCM.164.2.2011028

retrieved

21 January 2018

Pharmacokinetics of the nitric oxide synthase inhibitor L-NG-methylarginine hydrochloride in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1164%2FAJRCCM.164.2.2011028

retrieved

21 January 2018

The agonising negative trend in monitoring of clinical trials

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1164%2FAJRCCM.164.2.2011028

retrieved

21 January 2018

Increased survival after major thermal injury: the effect of growth hormone therapy in adults

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1164%2FAJRCCM.164.2.2011028

retrieved

21 January 2018

Identifiers

DOI

10.1164/AJRCCM.164.2.2011028

0 references

PubMed ID

11463585

0 references

(Q28186580)

Safeguarding patients in clinical trials with high mortality rates

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)